Menhycia

Menhycia is a quadrivalent meningococcal conjugate vaccine developed by CanSino Biologics for the prevention of epidemic cerebrospinal meningitis. The vaccine is composed of purified capsular polysaccharides from four serogroups of *Neisseria meningitidis* (A, C, Y, and W135), each covalently conjugated to the CRM197 carrier protein, a non-toxic mutant of the diphtheria toxin. This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, significantly improving immunogenicity and inducing immunological memory, particularly in infants and young children. Menhycia is indicated for active immunization in children aged 3 months to 6 years (83 months) and was the first quadrivalent meningococcal conjugate vaccine to be approved in China.

Brand names

Menhycia

Other names

Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)ACYW135 Meningococcal Conjugate VaccineACYW-135 Meningococcal Conjugate VaccineACYW 135 Meningococcal Conjugate VaccineMenACYW-CRM197MenACYW-CRM-197MenACYW-CRM 197CanSino MCV4